Tegavivint and gemcitabine for relapsed osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have osteosarcoma that has come back or not responded to treatment, and you must have received at least 3 of these drugs before: methotrexate, doxorubicin, cisplatin, or ifosfamide.
- You need to be at least 60 on a scale that measures your ability to do daily activities (like being up and about, even if in a wheelchair).
- You must have recovered from the side effects of any prior cancer treatments, with specific time gaps since your last treatment (for example, at least 2 weeks since chemotherapy, 7 days since certain targeted drugs, etc.).
- Your blood counts, kidney function, liver function, and heart function need to be within acceptable levels (tests will be done to check).
- You cannot have active, uncontrolled infections, certain bone metabolism disorders, or a history of organ or stem cell transplant.
- You must be willing to avoid certain medications (like strong CYP3A4 drugs, bisphosphonates, and denosumab) and use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
This trial tests a new drug called vactosertib for people with a type of bone cancer called osteosarcoma that has come back or hasn't responded to other treatments. The goal is to see if the drug can help shrink or slow the cancer and to check its safety.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
Hear when a new Osteosarcoma in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.